Skip to content

    Sagility India

    SAGILITYGood
    Information Technology·15 May 2025
    Management Summary

    Sagility India delivered a strong performance in FY25, meeting its guidance for mid-teen revenue growth and 24%+ EBITDA margins. The company successfully integrated the BroadPath acquisition, which significantly expanded its mid-market client base and onshore presence. Despite profitability pressures in the U.S. Medicare Advantage segment, management remains bullish, viewing client cost-cutting needs as an opportunity for further outsourcing and transformation work.

    Highlights

    7
    • Full-year FY25 revenue reached ₹5,569.9 crores ($658.3 million), representing 17.2% YoY growth in INR terms.

    • Q4 FY25 revenue stood at ₹1,568.5 crores ($181.8 million), up 22.2% YoY in INR terms and 17.7% in constant currency.

    • Adjusted EBITDA for FY25 was ₹1,468.5 crores, a 28.4% YoY increase, with margins at 26.4%.

    • Payer vertical grew 20.8% YoY, contributing 89.7% of revenue; Provider vertical grew 36.9% YoY.

    • Onboarded 38 new clients during the year, including 30 through the BroadPath acquisition.

    • Operating cash flow for FY25 was ₹1,214.1 crores, representing approximately 90% of reported EBITDA.

    • Reported EPS for FY25 grew by 119.3% YoY to ₹1.17 per share.

    What Changed2

    vs Q2 FY26

    Guidance items4 → 5 (+1)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹5,569.9 Cr+17.2%YoY
    2. 02Adjusted EBITDA Margin26.4%
    3. 03Adjusted PAT₹239.8 Cr+45.2%YoY
    4. 04Adjusted EPS₹1.76+27.7%YoY
    5. 05Attrition Rate27.5%0%YoY

    Segment breakdown

    Revenue ContributionYoY Growth
    Payer Vertical89.7%20.8%
    Provider Vertical10.3%36.9%
    Heatmap· 2 shared metrics

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Organic Revenue Growth (CC)
    low- to mid-teens
    High
    Revenue
    Total Revenue Growth (CC)
    >20%
    Medium
    Margin
    Steady-state Adjusted EBITDA Margin
    24-25%
    High
    Margin
    BroadPath EBITDA Margin Dilution
    120-150 bps
    High
    Debt
    Promoter Debt Repayment
    ₹820 crores
    High

    Risks & concerns

    4
    RiskSeverity

    Medicare Advantage Utilization Spikes

    High utilization in 2024 impacted client profitability, leading some to exit unprofitable segments.Both acknowledged

    medium

    AI Revenue Cannibalization

    Automation reduces effort/billing; currently 1.5-2% impact, expected to rise to 4-5% in 2-3 years.Both acknowledged

    low

    Forex Losses in Philippines

    Forex losses due to balance sheet restatement in the Philippines impacted Q4 margins by 80-90 bps.Management acknowledged

    low

    BroadPath Margin Dilution

    Acquisition is expected to dilute EBITDA margins by 120-150 bps in FY26.Management acknowledged

    medium

    Q&A highlights

    3

    “those profitability pressures in fact, have increased the propensity for clients to work with service providers like us.”

    Clarifies that client-side financial stress is a tailwind for outsourcing demand rather than a risk to Sagility's volumes.

    asked by Manik Taneja, Axis Capital

    2 min read5 chapters

    Detailed Narrative

    01

    BroadPath Acquisition Drives Mid-Market Expansion

    The acquisition of BroadPath has significantly altered Sagility's client profile, adding 30+ new clients primarily in the mid-market and smaller healthcare payer space. While the acquisition is currently dilutive to EBITDA margins by approximately 120-150 basis points, management expects to recover this through synergies in SG&A and vendor consolidation. Early cross-selling efforts are already underway, with active conversations with over 10 BroadPath clients regarding Sagility's broader service portfolio.

    02

    Navigating U.S. Healthcare Payer Headwinds

    Management addressed concerns regarding profitability pressures in the U.S. Medicare Advantage segment, noting that high utilization rates in 2024 have squeezed client margins. However, Sagility views this as a strategic opportunity, as clients under pressure are more likely to outsource core administrative processes to reduce costs. The company has seen no slowdown in its deal pipeline, adding eight new clients during the year and maintaining active final-stage negotiations with three more.

    03

    AI Strategy and Revenue Cannibalization

    Sagility is proactively managing the impact of GenAI and automation, which currently results in a 1.5% to 2% revenue cannibalization. This is expected to increase to 4-5% over the next 2-3 years as pilots move to full-scale implementation. The company's strategy is to remain margin-neutral by passing productivity gains to clients while charging for implementation and transformation, ensuring that their mid-teen growth guidance remains net of these impacts.

    04

    Margin Resilience Amidst Wage Hikes and Forex Volatility

    Despite a sequential dip in Q4 margins, management provided a clear bridge: 110 bps from BroadPath consolidation, 60-70 bps from January wage hikes, and 80-90 bps from forex losses in the Philippines. The company maintains a steady-state adjusted EBITDA margin target of 24-25% for FY26. They intend to continue investing in technology and healthcare-specific solutions (e.g., provider data management) to maintain long-term margin resilience.

    05

    Strong Cash Generation and Debt Deleveraging

    Sagility demonstrated robust cash flow generation, with free cash flow reaching 80.5% of EBITDA. The company funded the BroadPath acquisition entirely through internal accruals without additional borrowing. Management is committed to repaying the remaining ₹820 crore promoter debt over the next two years following a structured schedule, as prepayment is not an option under current regulatory frameworks. A formal dividend policy is expected to be announced within the next two quarters.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.